June 16, 2020

OICR joins European consortium to ‘enable and unlock biology in the open’

OICR’s Drug Discovery Program and the Structural Genomics Consortium join Europe’s new large-scale collaboration focused on generating open-access chemical tools for disease research and drug development

Richard Marcellus
Dr. Richard Marcellus, Principal Research Scientist and Group Leader in OICR’s Drug Discovery Program

Developing a new drug is a long, arduous and expensive process, requiring carefully-designed chemical compounds and the expertise to turn these compounds into medicines. In a massive international effort to accelerate this process, Europe’s Innovative Medicines Initiative (IMI) has recently launched a five-year, €66M, 22-partner consortium, EUbOPEN. OICR is a proud EUbOPEN partner.

Over the next five years, the consortium’s 22 participating organizations are teaming up to develop chemical probes and share those probes openly with the scientific community. Together, they will develop these chemical tool compounds for 1,000 proteins, representing a third of all druggable proteins in the human body.

Continue reading – OICR joins European consortium to ‘enable and unlock biology in the open’